Biosimilar for HER2+ breast cancer: Overall response rate matches reference trastuzumab

(European Society for Medical Oncology) The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study reported at the ESMO Asia 2019 Congress.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news